The stock of Edgewise Therapeutics Inc (EWTX) has gone down by -6.46% for the week, with a -16.19% drop in the past month and a 71.92% rise in the past quarter. The volatility ratio for the week is 5.26%, and the volatility levels for the past 30 days are 5.36% for EWTX. The simple moving average for the last 20 days is -7.79% for EWTX stock, with a simple moving average of 38.64% for the last 200 days.
Is It Worth Investing in Edgewise Therapeutics Inc (NASDAQ: EWTX) Right Now?
The stock has a 36-month beta value of 0.13. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EWTX is 62.41M, and at present, short sellers hold a 10.24% of that float. On December 05, 2024, the average trading volume of EWTX was 1.11M shares.
EWTX) stock’s latest price update
Edgewise Therapeutics Inc (NASDAQ: EWTX) has seen a decline in its stock price by -6.05 in relation to its previous close of 32.06. However, the company has experienced a -6.46% decline in its stock price over the last five trading sessions. businesswire.com reported 2024-11-26 that BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Evercore ISI repeating the rating for EWTX by listing it as a “Outperform.” The predicted price for EWTX in the upcoming period, according to Evercore ISI is $45 based on the research report published on November 22, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see EWTX reach a price target of $48. The rating they have provided for EWTX stocks is “Overweight” according to the report published on March 07th, 2024.
EWTX Trading at -6.52% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.99% of loss for the given period.
Volatility was left at 5.36%, however, over the last 30 days, the volatility rate increased by 5.26%, as shares sank -17.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.10% upper at present.
During the last 5 trading sessions, EWTX fell by -5.92%, which changed the moving average for the period of 200-days by +73.10% in comparison to the 20-day moving average, which settled at $32.67. In addition, Edgewise Therapeutics Inc saw 175.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Russell Alan J, who sale 75,000 shares at the price of $28.27 back on Sep 20 ’24. After this action, Russell Alan J now owns 12,719 shares of Edgewise Therapeutics Inc, valued at $2,120,101 using the latest closing price.
MOORE JOHN R, the General Counsel of Edgewise Therapeutics Inc, sale 50,000 shares at $28.37 during a trade that took place back on Sep 20 ’24, which means that MOORE JOHN R is holding 3,252 shares at $1,418,510 based on the most recent closing price.
Stock Fundamentals for EWTX
Current profitability levels for the company are sitting at:
- -65.34 for the present operating margin
- 0.29 for the gross margin
The net margin for Edgewise Therapeutics Inc stands at -55.19. The total capital return value is set at -0.3. Equity return is now at value -31.90, with -30.22 for asset returns.
Currently, EBITDA for the company is -112.81 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1251.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 26.35.
Conclusion
To sum up, Edgewise Therapeutics Inc (EWTX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
